Cordlife Group Limited ("Cordlife", together with its subsidiaries, the "Group") is a consumer healthcare company catering to the mother and child segment. Established in May 2001 and successfully listed on the Mainboard of Singapore Exchange Trading Limited ("SGX-ST") in 2012, the Group is one of the pioneers in the cord blood banking industry in Asia. Cordlife is amongst the leading players for private cord blood banking services in all the markets it operates in, namely Singapore, Hong Kong, Malaysia, India, Indonesia and the Philippines. Inhabiting a distinctive niche in the healthcare industry, the Group is one of the foremost private cord blood banks to have gained a solid foothold in Asia. In the last 17 years, Cordlife has dedicated its undertakings to achieve market leadership in the industry. Having built a distinguished brand name, the Group continues to strive for excellence by means of support from its experienced management team, dynamic key executives along with its quality product and service offerings. Cordlife believes the Group has in place a strong foundation for future expansion. The Group's processing and storage facilities in Hong Kong, India, Philippines and Singapore are accredited by AABB, the world's gold standard in cord blood banking and its facilities in Indonesia and the Philippines are also ISO-certified. Cordlife Singapore achieved accreditation by FACT-Netcord, making it one of only six cord blood banks in the world to achieve accreditations from both AABB and FACT-Netcord simultaneously. The Group’s majority owned Hong Kong and India subsidiaries, Hong Kong Screening Centre Limited (“HKSC”) and Cordlife Sciences (India) Pvt. Ltd. (“Cordlife India”), have also received accreditation from the College of American Pathologists (“CAP”), which is awarded to facilities that meet or exceed the highest standards in laboratory services. In July 2017, Cordlife Philippines became the first cord blood bank in the country to be accredited by AABB.